



## **Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies**

**Villepinte, June 14, 2017 – 6:00 pm CEST** - Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, today announced that it has signed an equity acquisition of fifteen million Euros in the BioMedTech fund (FPCI) managed by Truffle Capital which specializes in investing in start-ups developing technologies and breakthrough products in the life sciences sector.

The BioMedTech fund which targets 200 million Euros is dedicated to investments in a dozen essentially French start-ups. They are mostly MedTechs but some are also BioTechs working in the fields of minimally invasive interventional medicine (connected prostheses, interventional imaging, robotics, virtual biopsy, etc.) and biotechnology products offering breakthrough improvements, particularly in cardiovascular, osteoarticular, and infectious diseases, or neurology, dermatology, and oncology.

The Fund's investment criteria, particularly in the MedTech field are as follows:

- The development of a radical innovation, capable of changing the lives of patients;
- A product capable of becoming a “first-in-class” or “best-in-class”, world leader in its sector in 6-8 years;
- A very high level management team and Board of Directors, from the beginning of the activity;
- A broad and strong intellectual property portfolio with licensing freedom;
- Attractive sectors for industrial acquirers or for stock markets.

Truffle is highly skilled in detecting radical innovations in American and European universities and innovative companies with high growth potential. It has contributed effectively to the structuring and optimization of many life sciences investments.

## Press release

*“This investment completes Guerbet’s innovation strategy. We want to actively contribute to the development of new diagnostic or therapeutic solutions that are very innovative for the health of patients, particularly those based on minimally invasive, ambulatory or image-guided procedures. We appreciate Truffle Capital’s entrepreneurial approach and their focus on radical innovations in medicine,”* said Yves L'Epine, CEO of Guerbet.

*“We are very pleased Guerbet has so much confidence in us. Our past successes are based on proven sector-specific expertise, an entrepreneur-investor strategy, and on our ongoing search in the world’s leading universities for radical innovations to found start-ups that can change the lives of patients. With our new fund, we will help build tomorrow’s medicine with young companies, many of which could become global leaders,”* said Philippe Pouletty, Managing Director of Truffle Capital.

### About Guerbet

---

Guerbet is a pioneer in the contrast agent field with over 90 years’ of experience and is one of the leaders in medical imaging worldwide. It offers a full range of pharmaceutical products, medical devices and services for X-ray (RX) and Magnetic Resonance Imaging (MRI) scanners and Interventional Radiology and Theranostics (IRT) to improve the diagnosis and treatment of patients. With 7% of its revenue dedicated to R&D and more than 200 employees working in its three centers in France and the United States, Guerbet invests heavily in research and innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B – Mid Caps) and generated €776 million in revenue in 2016. For more information about Guerbet, visit <http://www.guerbet.com>

### About Truffle Capital

---

Truffle Capital is an independent European management company that was founded in 2001 by Philippe Pouletty MD, Bernard-Louis Roques and Henri Moulard. Today, Truffle Capital is chaired by Patrick Kron together with its co-founders Philippe Pouletty and Bernard-Louis Roques, both Managing Directors. Truffle Capital currently manages over 750 million Euros through retail funds (FCPI), institutional funds (FPCI), holding companies and asset management mandates. Truffle is specialized in the investment and support of companies that are developing disruptive technologies within two business sectors: the Life Sciences sector headed by Philippe Pouletty and the Information Technologies sector headed by Bernard -Louis Roques. For more information, visit [www.truffle.fr](http://www.truffle.fr)

### Contact

---

#### Alize RP

Caroline Carmagnol, Wendy Rigal

[truffle@alizerp.com](mailto:truffle@alizerp.com)

01 44 54 36 62 / 06 64 18 99 59